Category: Hot Mandates

China Investment Firm Seeks Novel Oncology/First-In-Class Therapeutic Drugs and Diagnostics

~ Next Phase Admin ~ Leave a comment

A biotech incubator sector fund founded in 2015 is headquartered in China with an additional USA office. The firm currently manages two venture funds including an RMB and USD fund. The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to tailor its incubator and CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities based in China and North America, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking in-licensing opportunities and plans to make 6-8 investments next year but is flexible.

The firm focuses mostly on therapeutics, while the firm is also open to Diagnostics. The firm can utilize its CRO services to advance portfolio company’s products into or through clinical trials. The firm is currently most interested in oncology-related small molecule drugs and first-in-class drugs. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. For therapeutics, the firm is looking to invest in pre-clinical stage. For diagnostics, the firm will consider companies from in-development to clinical stages. The firm will not invest in Medical Devices or Healthcare IT companies.

The firm looks to act as a lead investor in seed round investments and can participate as either lead or co-investor in series A investments. The firm is looking for companies with skilled and experienced management teams. The firm prefers to support companies that own exclusive IP protection with renowned universities or research institutions. The firm also prefers to work with companies that have a technical expert and experienced in clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Singapore-Based PE Firm Invests Up to $20M in All Areas of Life Sciences with Potential for Global Growth, Open to Any Stage of Development

~ Next Phase Admin ~ Leave a comment

A private equity and corporate finance advisory firm is headquartered in Singapore with a global presence. The firm makes global investments into life science and healthcare companies as well as services related to healthcare. The firm acts as a lead investor and utilizes their network to seek out other co-investors. Typical deal size is $0.5m to $20m. The firm will occasionally seek distribution rights for international investments.

The firm is interested in therapeutics, medical devices, diagnostics, healthcare IT, healthcare services, biotech, R&D services and suppliers and engineering companies. The firm is both stage and indication agnostic and has no revenue requirement. The firm has no flexible investment criteria but the East West Axis is very important as the firm is not interested in companies that are restricted to one country. The firm looks for companies with a multinational, global component.

The firm is flexible with their management team requirements. The firm is open to bringing in their own talent to assist with management and have supported scientists in becoming successful entrepreneurs. The firm is a value-added investor driven by opportunity. The firm takes a board seat when making investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm Seeks to Invest in Medical Device, Scientific Instrument, and Digital Health Technologies in the Midwest and Southern California

~ Next Phase Admin ~ Leave a comment

A venture capital firm located in the midwest USA with several offices nationwide. The firm has 3 funds, the third of which they are investing from. The third fund has a vintage year of 2016. The firm currently is looking to make investments from this fund typically in the $.25-1M range with 2x that amount saved for follow on investments. The firm is looking to make 10 investments a year through 2019. The firm typically invests in companies raising Seed Investments, Seed Extensions, or Series A investments. The firm tends to lead 30-40% of their investments and co-invests in the rest. The firm looks at companies primarily in the Midwest, but is also interested in companies in Southern California.

The firm looks for investments primarily in the healthcare IT, medical devices, scientific instruments, and agriculture technology spaces. For the healthcare IT, agriculture technology, and scientific instrument companies, the firm prefers for the companies to have demonstrated product-market fit, some decent revenue traction, and a good revenue trend-line. For the medical device companies, the firm prefers to invest in companies that are just prior to FDA approval or are going through the FDA approval process. The firm’s focus on IT is much broader than just healthcare IT and is willing to consider IT companies beyond the healthcare sector.

The firm looks for companies with experienced management teams. When leading the investments, the firm requests a board seat and when co-investing, the company requests board observer rights if possible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Hong Kong PE Firm Seeks to Invest Up to $10 M in Clinically Validated Medical Device and Diagnostics Products with China Angle

~ Next Phase Admin ~ Leave a comment

A PE firm that is headquartered in Hong Kong with additional offices throughout China currently manages over US$4 billion in assets and invests across several industry sectors including healthcare. The firm is interested in pre-growth and growth stage companies. Typical investment size ranges from US$5-10 million in Series A rounds. The firm seeks to lead but is open to syndicating with co-investors. The firm is now looking for opportunities in China, the US, and Canada.

Within healthcare, the firm focuses on medical devices and diagnostic technologies that have a China angle. The firm prefers products that have achieved clinical validation with proven advantages. The firm is also interested in clinical-stage biopharmaceutical opportunities as well as health information technology. The firm is opportunistic in terms of indication areas but is less interested in orphan diseases.

The firm is looking for experienced management teams with track record of success. The firm typically requests board representation in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Newly Established VC Fund Invests in Innovative Digital Health and Medtech/Diagnostics Technologies with Software Components

~ Next Phase Admin ~ Leave a comment

A new venture fund started investing in pre-seed, seed and Series A rounds. The firm’s main investment areas are in companies that advance and improve human health through novel models of care delivery and in companies that are at the cutting-edge of frontier technology, such as neurotech, brain/machine interfaces, genomics and AI. The firm will consider digital health companies as well as diagnostics and medical device companies, as long as they have a software component. The firm will only invest in companies with disruptive technology, not incremental innovations. The firm will invest between $.1-1.5M in the initial investment, with the possibility of participating in following rounds. The firm is willing to lead or co-invest, has made 7 investments to date and is looking to invest in 4-6 companies a year.

The firm will consider digital health companies that are focused on improving patient care. Ideally, companies will already have a pilot with some outcomes-based data indicating traction. The firm is also interested in medical device companies, but will only invest if there is a significant software and/or radical innovation component. The firm will also consider diagnostics, such as genomics-based technologies, but not in vitro diagnostics. The firm will not invest in traditional therapeutics (i.e. small molecule or biologics) companies but will consider software-as-medicine and bioelectronic medicine.

Due to the firm’s preference for cutting-edge technology, the firm prefers that there be at least one technical expert in the company leadership. If acting as a lead investor, the firm will take a board or board observer seat. The firm prefers to be an active investor, providing multi-faceted support to portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

~ Next Phase Admin ~ Leave a comment

A Seoul-based venture capital firm founded in 2015 and affiliated with a leading pharmaceutical company in South Korea closed their first fund in 2016 and has recently raised a second fund of approximately $60M USD. The firm has made 8 investments to date, in 3 Korean and 5 USA-based companies. The firm continues to seek global opportunities. The firm generally participates in financings of Series B and beyond, participating in Series A rounds on a case-by-case basis. However, the firm has started to look for earlier stage opportunities and is most interested in spin-out assets and forming new companies in South Korea. Within this angle, the firm is highly interested in companies who are interested in entering the Korean market and looking to leverage on the capital and clinical infrastructure in South Korea.

The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.

With regards to companies raising a Series A round, the firm prefers working with experienced management teams with high-profile scientific founders being involved. The firm incorporates a different strategy depending on the company’s headquarters. For companies based in South Korea, the firm serves as a hands-on, active investor and seeks board representation. In the USA, the firm prefers to be a more passive investor and generally seeks to co-invest with established venture capital firms that have a footprint in the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need

~ Next Phase Admin ~ Leave a comment

A boutique venture capital firm founded in Hong Kong currently manages a $100M USD fund and a $200M RMB fund. The fund is industry agnostic within China while it focuses only on healthcare ex-China. The firm generally participates in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $1-5M. The firm is open to both leading and co-investing. The firm is actively seeking new opportunities from across the world with a focus on companies in China, U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad.

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.

The firm is in search of ambitious companies with strong, experienced management teams. The firm takes a hands-on approach to portfolio companies and can work with incomplete teams. The firm can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. The firm may also request distribution or negotiation rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.